-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Dermata Therapeutics Reports Securities Purchase Deal With Single Institutional Investor To Buy ~$5M In Common Stock Priced At The Market
Dermata Therapeutics Reports Securities Purchase Deal With Single Institutional Investor To Buy ~$5M In Common Stock Priced At The Market
Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $5.0 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants, in a private placement priced at-the-market under Nasdaq rules.
Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one warrant to purchase one share of common stock at a combined purchase price of $1.325. Under the terms of the securities purchase agreement, Dermata has agreed to sell 3,773,585 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 3,773,585 shares of common stock. The warrants will be exercisable for a period of five years from the date of issuance and have an exercise price of $1.325 per share. The closing of the private placement is expected to occur on or about April 25, 2022, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement.
Maxim Group LLC is acting as the sole placement agent for the offering.
Dermata currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $5.0 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants, in a private placement priced at-the-market under Nasdaq rules.
Demata Treateutics,Inc.(“Demata”或“公司”)(納斯達克:DRMA)和(納斯達克:DRMAW)專注於治療醫療和美容皮膚疾病的臨牀期生物技術公司Inc.今天宣佈,它已與單一機構投資者簽訂了一項證券購買協議,將以私募方式購買約500萬美元的普通股(或用於購買普通股代替普通股的預資金權證)和認股權證,根據納斯達克規則按市價定價。
Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one warrant to purchase one share of common stock at a combined purchase price of $1.325. Under the terms of the securities purchase agreement, Dermata has agreed to sell 3,773,585 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 3,773,585 shares of common stock. The warrants will be exercisable for a period of five years from the date of issuance and have an exercise price of $1.325 per share. The closing of the private placement is expected to occur on or about April 25, 2022, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement.
每股普通股(或代替普通股的預融資認股權證)將與一份認股權證一起出售,以購買一股普通股,總購買價為1.325美元。根據證券購買協議的條款,德瑪塔已同意出售3,773,585股普通股(或作為替代的預融資權證)和認股權證,以購買總計3,773,585股普通股。這些認股權證的行使期為五年,自發行之日起計,行使價為每股1.325美元。私募預計將於2022年4月25日左右完成,前提是滿足證券購買協議中規定的某些慣常完成條件。
Maxim Group LLC is acting as the sole placement agent for the offering.
Maxim Group LLC是此次發行的唯一配售代理。
Dermata currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
德瑪塔目前打算將此次發行的淨收益用於營運資金和一般企業用途。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧